Related Experiment Video
Updated: Jul 1, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Biologic therapies in pediatric psoriasis: A single-center experience
Sabrina Merenzon1, Paula C Luna1, María E Abad1
1Department of Dermatology, Hospital Alemán, Autonomous City of Buenos Aires, Argentina.
None:
Pediatric psoriasis accounts for approximately 2% of dermatological conditions in children under 16 years of age. The objective of this study is to describe the clinical characteristics, treatment regimens, and observed efficacy and safety profiles in a real-world cohort. This retrospective study analyzed 15 pediatric patients treated with biologics in Argentina between 2010 and 2024. The median age at treatment initiation was 8 years, with a predominance of female patients. The biologics used were primarily adalimumab, followed by secukinumab, etanercept, and ixekizumab. Five patients experienced treatment failure secondary to adalimumab. The therapy was well tolerated, with no adverse events reported.The data suggest that early intervention can alter the course of the disease and prevent long-term complications.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
iPS Cell Differentiation